QLT, Xenova in cancer deal

Xenova (LSE:XEN; XNVA) granted QLTI exclusive development and marketing rights in the U.S., Canada and Mexico to its XR9576, a P-glycoprotein multi-drug resistance (MDR) inhibitor in Phase II testing ...